HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue...

Related Keywords

United States , Luis Sanay , Jeffreym Dayno , Drug Administration , Paragon Biosciences , Zynerba Pharmaceuticals , Exchange Commission , Prnewswire Harmony Biosciences Holdings Inc , Share Repurchase Program , Nasdaq , Preliminary Net Revenue , Fourth Quarter , Full Year , Representing Growth , Product Revenue Projected Between , Common Stock Repurchase , Fourth Quarter Bringing , Continue Opportunistic Share Repurchases , Biosciences Holdings , Healthcare Conference , Harmony President , Product Revenue , Strong Growth , Net Revenue , Idiopathic Hypersomnia , Myotonic Dystrophy Type , Capital Allocation , Maximize Shareholder , Full Prescribing Information , Harmony Biosciences , Plymouth Meeting , Private Securities Litigation Reform Act , Annual Report , Biosciences Investor Contact , Biosciences Media Contact ,